These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 29137021)
21. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480 [TBL] [Abstract][Full Text] [Related]
22. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316 [TBL] [Abstract][Full Text] [Related]
23. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. O'Shaughnessy J; Schwartzberg L; Danso MA; Miller KD; Rugo HS; Neubauer M; Robert N; Hellerstedt B; Saleh M; Richards P; Specht JM; Yardley DA; Carlson RW; Finn RS; Charpentier E; Garcia-Ribas I; Winer EP J Clin Oncol; 2014 Dec; 32(34):3840-7. PubMed ID: 25349301 [TBL] [Abstract][Full Text] [Related]
24. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871 [TBL] [Abstract][Full Text] [Related]
25. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. Chen H; Lu W; Zhang Y; Zhu X; Zhou J; Chen Y Cancer Med; 2019 Jan; 8(1):383-399. PubMed ID: 30525293 [TBL] [Abstract][Full Text] [Related]
26. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E; Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393 [TBL] [Abstract][Full Text] [Related]
27. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis. Liu Z; Li J; Zhao F; Ren D; Li Z; Chen Y; Huang S; Liu Z; Zhao Y; Wang M; Li H; Xu Z; Shen G; Zhao J BMC Cancer; 2024 Apr; 24(1):440. PubMed ID: 38594636 [TBL] [Abstract][Full Text] [Related]
28. The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials. Wang X; Huang C; Li M; Gu Y; Cui Y; Li Y Tumour Biol; 2014 May; 35(5):4841-8. PubMed ID: 24570182 [TBL] [Abstract][Full Text] [Related]
29. Neo-adjuvant therapy for triple-negative breast cancer: Insights from a network meta-analysis. Miyashita H; Satoi S; Cruz C; Malamud SC Breast J; 2020 Sep; 26(9):1717-1728. PubMed ID: 32657479 [TBL] [Abstract][Full Text] [Related]
30. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related]
31. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131 [TBL] [Abstract][Full Text] [Related]
32. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis. Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530 [TBL] [Abstract][Full Text] [Related]
33. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802 [TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response. Weng ZJ; Wu SX; Luo HS; Du ZS; Li XY; Lin JZ Inquiry; 2021; 58():469580211056213. PubMed ID: 34806458 [TBL] [Abstract][Full Text] [Related]
35. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620). Malhotra MK; Pahuja S; Kiesel BF; Appleman LJ; Ding F; Lin Y; Tawbi HA; Stoller RG; Lee JJ; Belani CP; Chen AP; Giranda VL; Shepherd SP; Emens LA; Ivy SP; Chu E; Beumer JH; Puhalla S Breast Cancer Res Treat; 2023 Apr; 198(3):487-498. PubMed ID: 36853577 [TBL] [Abstract][Full Text] [Related]
36. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026 [TBL] [Abstract][Full Text] [Related]
37. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622 [TBL] [Abstract][Full Text] [Related]